MedTrace Logo

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00066729 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-10-04

Study results available
· View outcomes & findings →

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: A phase I trial to study the side effects of vaccine therapy in patients with ovarian epithelial, primary peritoneal, or fallopian tube cancer.

Conditions

Interventions

BIOLOGICAL

NY-ESO-1 peptide vaccine

NY-ESO-1b peptide 100 μg mixed with 0.5 mL of Montanide® ISA-51

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Ludwig Institute for Cancer Research

    lead OTHER

Principal Investigators

  • Jakob Dupont, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-23
Primary Completion
2006-05-09
Completion
2013-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00066729 on ClinicalTrials.gov